Global cholera vaccines market is anticipated to grow significantly with a CAGR of 10% during forecast period due to rising government initiatives in immunization program and growing incidence of cholera particularly in developing countries in Asia and Africa would drive the growth of cholera vaccines market globally.
Cholera is an infection of the small intestine by strains of the bacterium Vibrio cholera, which can cause death of the patient if left untreated. According to the World Health Organization (WHO) every year there are 1.3 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths worldwide; it is affected primarily in Africa, South and Southeast Asia, and South Americas. Some factors such as higher prevalence of cholera in some African and south Asian countries and government initiative in immunization program are prime factors that driving the growth of cholera vaccines market globally. For the purpose of study market is segmented on the basis of product type such as dukoral, shanchol, vaxchora and others vaccines and geography. It is studied that, there are three WHO-prequalified, killed, whole-cell oral cholera vaccines are currently extensively use in market; among these Dukoral was observed as largest revenue contributing segment because it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries and it prevent diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC) are primarily driving the growth of Dukoral market globally.
For the purpose of this study, the global cholera vaccines market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets. These regional markets are further sub-segmented into top country level markets that majorly determine the regional industry trends. Among the considered regional markets, Asia Pacific currently dominates the global cholera vaccines market because large number of affected populations in South-East Asian countries and government initiatives in immunization program are prime factors that driving the market growth in Asia Pacific. However, it is estimated that North America will show the highest growth during forecast period and growth will mainly fuel by a new approved oral vaccine Vaxchora, as it is the only vaccine available in the United States for protection against cholera.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global cholera vaccines market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global cholera vaccines market. This report concludes with company profiles section that highlights major information about the key players engaged in global cholera vaccines market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.
It is studied that in the base year 2021, Dukoral held largest market share, due to some factors such as it is the only approved cholera vaccine available for European, Canadian and Australian travelers, it prevents diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC), it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries are primarily driving the growth of Dukoral market. On the other hand Vaxchora will expected to show significant growth during forecast period due to government recommendation for use in adults 18 through 64 years of age traveling to cholera-affected areas, it is the only vaccine available in the United States for protection against cholera and the only single dose vaccine for cholera currently licensed anywhere in the world these factors would expected to drive the market during forecast period.
According to World Health Organization (WHO), cholera represents an estimated burden of 1.4 to 4.0 million cases, and 21,000 to 143,000 deaths per year worldwide. For the purpose of this study, the global cholera market is regionally categorized as North America, Europe, Asia Pacific, LATAM and MEA; among the considered regional markets North America is expected to dominate the cholera market during forecast period due to higher healthcare awareness among general population, government initiatives in treatment and awareness program, higher cost of vaccines and presence of key manufacturer would drive the market growth in North America, recently approved vaxchora would primarily assist market growth in North America. Centers for Disease Control and Prevention (CDC) recommendation for travelers to cholera-affected regions would fuel the market growth in United States. On the other hand, Asia Pacific is currently dominating the Cholera vaccines market due to increasing awareness of immunization, higher number of targeted population and government initiatives in awareness program are primarily driving the market growth in Asia Pacific.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
Cholera is an infection of the small intestine by strains of the bacterium Vibrio cholera, which can cause death of the patient if left untreated. According to the World Health Organization (WHO) every year there are 1.3 to 4.0 million cases of cholera, and 21,000 to 143,000 deaths worldwide; it is affected primarily in Africa, South and Southeast Asia, and South Americas. Some factors such as higher prevalence of cholera in some African and south Asian countries and government initiative in immunization program are prime factors that driving the growth of cholera vaccines market globally. For the purpose of study market is segmented on the basis of product type such as dukoral, shanchol, vaxchora and others vaccines and geography. It is studied that, there are three WHO-prequalified, killed, whole-cell oral cholera vaccines are currently extensively use in market; among these Dukoral was observed as largest revenue contributing segment because it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries and it prevent diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC) are primarily driving the growth of Dukoral market globally.
For the purpose of this study, the global cholera vaccines market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets. These regional markets are further sub-segmented into top country level markets that majorly determine the regional industry trends. Among the considered regional markets, Asia Pacific currently dominates the global cholera vaccines market because large number of affected populations in South-East Asian countries and government initiatives in immunization program are prime factors that driving the market growth in Asia Pacific. However, it is estimated that North America will show the highest growth during forecast period and growth will mainly fuel by a new approved oral vaccine Vaxchora, as it is the only vaccine available in the United States for protection against cholera.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global cholera vaccines market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global cholera vaccines market. This report concludes with company profiles section that highlights major information about the key players engaged in global cholera vaccines market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report.
It is studied that in the base year 2021, Dukoral held largest market share, due to some factors such as it is the only approved cholera vaccine available for European, Canadian and Australian travelers, it prevents diarrhea caused by Vibrio cholera and heat-labile toxin producing enterotoxigenic Escherichia coli (ETEC), it is the prequalified by World Health Organization (WHO) and has been licensed in more than 60 countries are primarily driving the growth of Dukoral market. On the other hand Vaxchora will expected to show significant growth during forecast period due to government recommendation for use in adults 18 through 64 years of age traveling to cholera-affected areas, it is the only vaccine available in the United States for protection against cholera and the only single dose vaccine for cholera currently licensed anywhere in the world these factors would expected to drive the market during forecast period.
Asia Pacific Dominates the market
In the base 2021, Asia Pacific was observed as the largest market for cholera vaccines because large pool of patients suffering with cholera, increasing healthcare awareness, government initiatives in treatment and awareness program are primarily driving the market growth in Asia Pacific. On the other hand North America expected to show fastest growth during forecast period because Vaxchora is the only vaccine available in the United States for protection against cholera and recommended use in adults 18 through 64 years of age traveling to cholera-affected areas would expected to assist the market growth in North America.According to World Health Organization (WHO), cholera represents an estimated burden of 1.4 to 4.0 million cases, and 21,000 to 143,000 deaths per year worldwide. For the purpose of this study, the global cholera market is regionally categorized as North America, Europe, Asia Pacific, LATAM and MEA; among the considered regional markets North America is expected to dominate the cholera market during forecast period due to higher healthcare awareness among general population, government initiatives in treatment and awareness program, higher cost of vaccines and presence of key manufacturer would drive the market growth in North America, recently approved vaxchora would primarily assist market growth in North America. Centers for Disease Control and Prevention (CDC) recommendation for travelers to cholera-affected regions would fuel the market growth in United States. On the other hand, Asia Pacific is currently dominating the Cholera vaccines market due to increasing awareness of immunization, higher number of targeted population and government initiatives in awareness program are primarily driving the market growth in Asia Pacific.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cholera Vaccines market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Cholera Vaccines market and their expected impact during the forecast period.
Market Segmentation
Product
- Dukoral
- Shanchol
- Vaxchora
- Others
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Cholera Vaccines market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Cholera Vaccines market?
- Which is the largest regional market for Cholera Vaccines market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East Africa?
- Which are the key trends driving Cholera Vaccines market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Cholera Vaccines market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Cholera Vaccines Market
2.2. Global Cholera Vaccines Market, By Product, 2021 (US$ Million)
2.3. Global Cholera Vaccines Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Cholera Vaccines Market: Competitive Analysis
3.1. Market Positioning of Key Cholera Vaccines Market Vendors
3.2. Strategies Adopted by Cholera Vaccines Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Cholera Vaccines Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Cholera Vaccines Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Dukoral
5.3.2. Shanchol
5.3.3. Vaxchora
5.3.4. Others
6. North America Cholera Vaccines Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
6.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
7. UK and European Union Cholera Vaccines Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
7.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
8. Asia Pacific Cholera Vaccines Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
8.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
9. Latin America Cholera Vaccines Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
9.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
10. Middle East and Africa Cholera Vaccines Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
10.3.Cholera Vaccines Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Cholera Vaccines Market: By Product, 2020-2030, USD (Million)
11. Company Profile
11.1. Astellas Pharma, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Sonofi
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Emergent BioSolutions, Inc. (PaxVax, Inc.)
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Valneva SE
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Eubiologics Co. Ltd.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. GlaxoSmithKline plc (GSK)
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Merck & Co., Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Celldex Therapeutics, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Mitsubishi Tanabe Pharma Corporation
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Takeda Pharmaceutical Co. Ltd
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Johnson & Johnson (Crucell)
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
List of Figures
Figure 1 Global Cholera Vaccines Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Cholera Vaccines Market: Quality Assurance
Figure 5 Global Cholera Vaccines Market, By Product, 2021
Figure 6 Global Cholera Vaccines Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Cholera Vaccines Market, 2021
Figure 8 Market Positioning of Key Cholera Vaccines Market Players, 2021
Figure 9 Global Cholera Vaccines Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Cholera Vaccines Market, By Product, 2021 Vs 2030, %
Figure 11 U.S. Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 12 Canada Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 14 UK Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 15 Germany Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 16 Spain Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 17 Italy Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 18 France Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 20 China Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 21 Japan Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 22 India Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 23 Australia Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 24 South Korea Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 26 Brazil Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 27 Mexico Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 29 GCC Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 30 Africa Cholera Vaccines Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Cholera Vaccines Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 2 North America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 3 U.S. Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 4 Canada Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 5 Rest of North America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 6 UK and European Union Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 7 UK Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 8 Germany Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 9 Spain Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 10 Italy Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 11 France Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 12 Rest of Europe Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 13 Asia Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 14 China Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 15 Japan Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 16 India Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 17 Australia Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 18 South Korea Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 19 Latin America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 20 Brazil Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 21 Mexico Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 22 Rest of Latin America Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 23 Middle East and Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 24 GCC Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 25 Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Table 26 Rest of Middle East and Africa Cholera Vaccines Market By Product, 2020-2030, USD (Million)
Companies Mentioned
- Astellas Pharma Inc.
- Sonofi
- Emergent BioSolutions Inc. (PaxVax Inc.)
- Valneva SE
- Eubiologics Co. Ltd.
- GlaxoSmithKline plc (GSK)
- Merck & Co. Inc.
- Celldex Therapeutics Inc.
- Mitsubishi Tanabe Pharma Corporation
- Takeda Pharmaceutical Co. Ltd
- Johnson & Johnson (Crucell)
